D. E. Shaw & Co., Inc. Novo Cure LTD Put Options Transaction History

D. E. Shaw & Co., Inc.

11 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q2 2024 Aug 14, 2024	BUY	$11.83 - $24.05 $300,482 - $610,870	25,400 Added 61.5%	66,700 $1.14 Million
Q1 2024 May 15, 2024	BUY	$12.42 - $17.29 $512,946 - $714,077	41,300 New	41,300 $645,000
Q1 2022 May 16, 2022	SELL	$60.15 - $84.52 $1.8 Million - $2.54 Million	-30,000 Reduced 75.0%	10,000 $829,000
Q3 2021 Nov 15, 2021	BUY	$116.17 - $194.55 $1.16 Million - $1.95 Million	10,000 Added 33.33%	40,000 $4.65 Million
Q2 2021 Aug 16, 2021	BUY	$130.4 - $225.58 $2.61 Million - $4.51 Million	20,000 Added 200.0%	30,000 $6.66 Million
Q1 2021 May 17, 2021	SELL	$124.11 - $190.17 $1.18 Million - $1.81 Million	-9,500 Reduced 48.72%	10,000 $1.32 Million
Q4 2020 Feb 16, 2021	BUY	$112.16 - $174.14 $44,864 - $69,656	400 Added 2.09%	19,500 $3.37 Million
Q2 2020 Aug 14, 2020	SELL	$57.2 - $74.41 $623,480 - $811,069	-10,900 Reduced 36.33%	19,100 $1.13 Million
Q1 2020 May 15, 2020	BUY	$57.05 - $95.75 $718,830 - $1.21 Million	12,600 Added 72.41%	30,000 $2.02 Million
Q3 2019 Nov 14, 2019	SELL	$61.86 - $97.8 $160,836 - $254,280	-2,600 Reduced 13.0%	17,400 $1.3 Million
Q1 2019 May 15, 2019	BUY	$31.96 - $56.12 $639,200 - $1.12 Million	20,000 New	20,000 $963,000

262

77M

1.17M

318K

Ticker NVCR
Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Shares Outstandng 104,950,000
Market Cap $1.86B
Description
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.